Curanex Pharmaceuticals (NASDAQ:CURX) Shares Down 8.7% – Here’s What Happened

Posted by Kyle Jackson on Jun 7th, 2026

Shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX – Get Free Report) traded down 8.7% during mid-day trading on Friday . The stock traded as low as $0.3007 and last traded at $0.3030. 111,359 shares traded hands during mid-day trading, an increase of 70% from the average session volume of 65,523 shares. The stock had previously closed at $0.3320.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on Curanex Pharmaceuticals

Curanex Pharmaceuticals Trading Down 8.7%

The stock has a market capitalization of $8.59 million and a price-to-earnings ratio of -1.12. The stock’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.39.

Curanex Pharmaceuticals (NASDAQ:CURX – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter.

Hedge Funds Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

(Get Free Report)

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.